Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma is a research paper published in Molecular Carcinogenesis (2023). On theSindex it has a DataRank of 0. It has been cited 5 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: P30CA046934
NCI NIH HHS
Grant: R03 CA249571
NCATS NIH HHS
Grant: UL1 TR002535
NCI NIH HHS
Grant: R37 CA261987
NCI NIH HHS
Grant: P30 CA060553
NIGMS NIH HHS
Grant: P41 GM108569
Congressionally Directed Medical Research Programs
National Institutes of Health
Cancer League of Colorado
Colorado Clinical and Translational Sciences Institute
MeSH Terms
Keywords